Pfizer (MIC:PFE-RM) Moat Score: 8/10 (As of Jul. 07, 2026)


What is Pfizer Moat Score?

Pfizer MIC:PFE-RM 72 Moat Score is 8 as of Jul. 07, 2026. GuruFocus rates MIC:PFE-RM with a GF Score™ of 72/100. The stock has 5 warning signs investors should review. Among 1,032 Drug Manufacturers companies, Pfizer ranks better than 99.71% on this metric.

Pfizer has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

Pfizer has Wide Moat: Pfizer benefits from a robust portfolio of patented drugs, strong brand recognition, and significant R&D capabilities. Its economies of scale and regulatory expertise create high barriers to entry. The company's pricing power and global distribution network further solidify its competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Pfizer might have Wide Moat - Clear and robust wide moat.

Pfizer  (MIC:PFE-RM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Pfizer Moat Score Related Terms

MIC:PFE-RM vs GILD, BMY, AMGN: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pfizer Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Moat Score distribution charts can be found below:

* The bar in red indicates where Pfizer's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 8 mean?
Pfizer (MIC:PFE-RM) has a Moat Score of 8 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Pfizer ranks #3 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Pfizer's Moat Score too high?
Pfizer's current Moat Score is 8. Based on the distribution chart, Pfizer ranks #3 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pfizer has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Moat Score compare to GILD and BMY?
According to the Drug Manufacturers industry distribution chart, Pfizer ranks #3 out of 1032 companies for Moat Score. This places Pfizer in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Pfizer's current Moat Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Pfizer (MIC:PFE-RM) has a current Moat Score of 8. The current Moat Score is 8. Pfizer's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Pfizer (MIC:PFE-RM), the current Moat Score is 8 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.